Feiba 500 U & 1000 U 500 U & 1000 U Powder and solvent for solution for injection
PDF Leaflet Revision Date: 26 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and prevention of bleeding in patients with haemophilia A or B with inhibitors.
Dosage (summary)
50-100 U/kg bodyweight, max 200 U/kg/day; adjust based on bleeding severity.
Special Populations
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Safety not established; increased risk of thrombosis in pregnancy.
Key Drug Interactions
- Antifibrinolytics
- Recombinant Factor VIIa
- Emicizumab
Contraindications
- Hypersensitivity
- DIC
- Acute thrombosis or embolism
Common side effects
- Hypersensitivity reactions
- Thrombosis
- Headache
- Nausea
Counselling Points
- Monitor for signs of hypersensitivity
- Do not exceed recommended doses
- Inform about potential thromboembolic risks
Serious warnings
- Risk of thromboembolic events
- Monitor for DIC
- Allergic reactions
Important Disclaimer
The Feiba 500 U & 1000 U 500 U & 1000 U Powder and solvent for solution for injection professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
